Taxus Cardium Pharmaceuticals Group (CRXM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2013 | 03-2013 | 12-2012 | 09-2012 | 06-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -4,380 | -2,262 | -8,323 | -6,364 | -4,470 |
| Depreciation Amortization | 184 | 93 | 281 | 174 | 116 |
| Accounts receivable | 195 | 134 | -183 | -4 | -10 |
| Accounts payable and accrued liabilities | -54 | -110 | -182 | -377 | -111 |
| Other Working Capital | 289 | 20 | -1,311 | -943 | -650 |
| Other Operating Activity | -175 | 52 | 505 | 446 | 143 |
| Operating Cash Flow | $-3,941 | $-2,074 | $-9,213 | $-7,068 | $-4,981 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -5 | -5 | -16 | -16 | -16 |
| Net Acquisitions | N/A | N/A | 288 | 288 | N/A |
| Investing Cash Flow | $-5 | $-5 | $272 | $272 | $-16 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | N/A | 1 | 1 | N/A |
| Other Financing Activity | 2,276 | 116 | 6,546 | 6,546 | 6,547 |
| Financing Cash Flow | $2,276 | $116 | $6,547 | $6,547 | $6,547 |
| Beginning Cash Position | 2,328 | 2,328 | 4,721 | 4,721 | 4,721 |
| End Cash Position | 659 | 365 | 2,328 | 4,472 | 6,272 |
| Net Cash Flow | $-1,670 | $-1,963 | $-2,393 | $-249 | $1,550 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,941 | -2,074 | -9,213 | -7,068 | -4,981 |
| Capital Expenditure | -5 | -5 | -16 | -16 | -16 |
| Free Cash Flow | -3,946 | -2,079 | -9,229 | -7,084 | -4,997 |